Literature DB >> 10869302

Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.

M Dandri1, M R Burda, H Will, J Petersen.   

Abstract

The aim of this study was to evaluate the inhibitory effect of the nucleotide analogue adefovir on woodchuck hepatitis B virus (WHV) replication and, in particular, to determine whether the pool of covalently closed circular DNA (cccDNA) could be reduced by adefovir treatment in primary cultures of woodchuck hepatocytes isolated from a chronic carrier. Strong reduction of WHV-DNA synthesis (90%) and secretion (up to 98%) was observed with all 3 doses of adefovir used (1, 10, and 100 micromol/L), whereas in the absence of the drug, high amounts of viral particles were continuously secreted in the culture medium until the end of the study (27 days). Secretion of envelope proteins and viral RNA levels remained constant both in the adefovir-treated and -untreated cultures for the entire course of the study. Intracellular core protein levels declined by approximately 50% in all the cultures, independent of adefovir treatment. There was no indication of cccDNA loss in the adefovir-treated hepatocyte cultures even when cell turnover was induced for 14 days by the addition of epidermal growth factor (EGF) to the culture medium. Our data show that adefovir has a very strong inhibitory effect on WHV-DNA synthesis in chronically infected primary hepatocyte cultures and indicate that cccDNA is a very stable molecule that appears to be efficiently transmitted to the dividing hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10869302     DOI: 10.1053/jhep.2000.8701

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  29 in total

1.  Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication.

Authors:  William R Addison; Kathie-Anne Walters; Winnie W S Wong; John S Wilson; Danuta Madej; Lawrence D Jewell; D Lorne J Tyrrell
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 2.  Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics.

Authors:  Ju-Tao Guo; Haitao Guo
Journal:  Antiviral Res       Date:  2015-08-10       Impact factor: 5.970

3.  In situ analysis of intrahepatic virological events in chronic hepatitis B virus infection.

Authors:  Xiaonan Zhang; Wei Lu; Ye Zheng; Weixia Wang; Lu Bai; Liang Chen; Yanling Feng; Zhanqing Zhang; Zhenghong Yuan
Journal:  J Clin Invest       Date:  2016-02-22       Impact factor: 14.808

Review 4.  Molecular biology of hepatitis B virus infection.

Authors:  Christoph Seeger; William S Mason
Journal:  Virology       Date:  2015-03-07       Impact factor: 3.616

Review 5.  Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential.

Authors:  Masaru Enomoto; Akihiro Tamori; Shuhei Nishiguchi; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2013-01-22       Impact factor: 7.527

Review 6.  How will we use the new antiviral agents for hepatitis B?

Authors:  Robert P Perrillo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

7.  Hepatocyte-like cells transdifferentiated from a pancreatic origin can support replication of hepatitis B virus.

Authors:  Robert Yung-Liang Wang; Chia-Ning Shen; Min-Hui Lin; David Tosh; Chiaho Shih
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Alpha/beta interferon differentially modulates the clearance of cytoplasmic encapsidated replication intermediates and nuclear covalently closed circular hepatitis B virus (HBV) DNA from the livers of hepatocyte nuclear factor 1alpha-null HBV transgenic mice.

Authors:  Aimee L Anderson; Krista E Banks; Marco Pontoglio; Moshe Yaniv; Alan McLachlan
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Authors:  Maura Dandri; Joerg Petersen
Journal:  Clin Infect Dis       Date:  2016-06-01       Impact factor: 9.079

10.  Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication.

Authors:  Jie Wang; Zhong-Wei Xu; Shuang Liu; Rui-Yang Zhang; Shan-Long Ding; Xiao-Meng Xie; Lu Long; Xiang-Mei Chen; Hui Zhuang; Feng-Min Lu
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.